The White House is prepar­ing to un­veil sev­er­al new deals with large drug­mak­ers on Fri­day as part of the ad­min­is­tra­tion’s “most fa­vored na­tion” pric­ing push, ac­cord­ing to sources fa­mil­iar with the plans.

The an­nounce­ment is like­ly to mim­ic oth­er re­cent most fa­vored na­tion un­veil­ings, with com­pa­ny CEOs and Pres­i­dent Don­ald Trump in the Oval Of­fice, said the sources, all of whom spoke on con­di­tion of anonymi­ty be­cause the an­nounce­ment isn’t yet pub­lic.

The ad­min­is­tra­tion has been work­ing to fi­nal­ize the deals, un­der which drug­mak­ers have agreed to cash-pay prices for some drugs, and to give the gov­ern­ment dis­counts on oth­ers in Medicare or Med­ic­aid. So far, Pfiz­er, As­traZeneca, Eli Lil­ly, No­vo Nordisk and EMD Serono have made deals.

The Biose­cure Act is slat­ed to be­come law af­ter the Sen­ate on Wednes­day passed a de­fense bill that in­cludes the mea­sure.

It's a de­vel­op­ment that once would have sent pan­ic through drug­mak­er board­rooms. But the leg­is­la­tion has since been weak­ened. Biose­cure would re­strict fed­er­al con­tracts with bio­phar­ma sup­pli­ers deemed for­eign ad­ver­saries, though un­like ear­li­er drafts, it stops short of nam­ing the ubiq­ui­tous con­trac­tors WuXi AppTec and WuXi Bi­o­log­ics.

Sens. Bill Hager­ty (R-TN) and Gary Pe­ters (D-MI) re­vived the leg­is­la­tion this sum­mer fol­low­ing in­flu­en­tial op­po­si­tion.

Last year, Rep. Jim Mc­Gov­ern (D-MA) and Sen. Rand Paul (R-KY) killed Biose­cure by ar­gu­ing it lacks due process for the WuXi en­ti­ties. That led to a com­pro­mise ver­sion that no longer names spe­cif­ic com­pa­nies. In­stead, the lat­est it­er­a­tion im­pos­es re­stric­tions on com­pa­nies that are on fed­er­al watch­lists. The Sen­ate vot­ed in Oc­to­ber to at­tach this new ver­sion to the an­nu­al de­fense pol­i­cy bill.

HHS Sec­re­tary Robert F. Kennedy Jr. added two con­di­tions to a fed­er­al new­born screen­ing list, re­viv­ing ef­forts that had been stalled un­der the Trump ad­min­is­tra­tion — though the process for adding more dis­eases is still un­cer­tain.

Dur­ing an HHS event on Tues­day, Kennedy said metachro­mat­ic leukody­s­tro­phy (MLD) and Duchenne mus­cu­lar dy­s­tro­phy will be placed on the fed­er­al gov­ern­ment’s Rec­om­mend­ed Uni­form Screen­ing Pan­el. Drug­mak­ers and pa­tient ad­vo­cates wel­comed the de­ci­sion, af­ter warn­ing that de­lays could im­per­il ac­cess to crit­i­cal ther­a­pies.

In April, an ex­ec­u­tive or­der signed by Pres­i­dent Don­ald Trump to elim­i­nate “un­nec­es­sary” fed­er­al func­tions shut down the Ad­vi­so­ry Com­mit­tee on Her­i­ta­ble Dis­or­ders in New­borns and Chil­dren. The com­mit­tee rec­om­mends dis­eases to screen for at birth, though states typ­i­cal­ly adopt the rec­om­men­da­tions whole­sale over time.